About
Hybrigenics is a bio-pharmaceutical company listed (ALHYG) on the Euronext Growth market of Euronext Paris. Inecalcitol is a vitamin D receptor agonist active by oral administration. Oral inecalcitol had shown excellent tolerance and presumption of efficacy for the first-line treatment of metastastic...
Hybrigenics is a bio-pharmaceutical company listed (ALHYG) on the Euronext Growth market of Euronext Paris. Inecalcitol is a vitamin D receptor agonist active by oral administration. Oral inecalcitol had shown excellent tolerance and presumption of efficacy for the first-line treatment of metastastic castrate-resistant prostate cancer in combination with Taxotere® . Inecalcitol had also been tested in two pilot clinical Phase II studies in chronic myeloid leukemia and chronic lymphocytic leukemia. Inecalcitol has failed to prolong overall survival of elderly acute myeloid leukemia patients in an international double-blind placebo-controlled Phase II clinical study. Hybrigenics has collaborated with Servier on one particular USP in oncology. In this R&D program, two milestones have been reached and additional milestones may be achieved until registration of a potential drug. Hybrigenics Pharma Inc., based in Cambridge, Mass., is the U.S. subsidiary of Hybrigenics.
You are not authorized to access this content.